These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30098968)

  • 1. Cardiac Resynchronization Therapy in Inotrope-Dependent Heart Failure Patients: A Systematic Review and Meta-Analysis.
    Hernandez GA; Blumer V; Arcay L; Monge J; Viles-Gonzalez JF; Lindenfeld J; Goldberger JJ; Chaparro S
    JACC Heart Fail; 2018 Sep; 6(9):734-742. PubMed ID: 30098968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of outcomes for patients with nonischemic cardiomyopathy taking intravenous inotropes versus those weaned from or never taking inotropes at cardiac resynchronization therapy.
    Adelstein E; Bhattacharya S; Simon MA; Gorcsan J; Saba S
    Am J Cardiol; 2012 Sep; 110(6):857-61. PubMed ID: 22681865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure.
    Herweg B; Ilercil A; Cutro R; Dewhurst R; Krishnan S; Weston M; Barold SS
    Am J Cardiol; 2007 Jul; 100(1):90-3. PubMed ID: 17599447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of cardiac resynchronisation therapy in the treatment of end-stage inotrope-dependent heart failure patients.
    Sokal A; Jędrzejczyk E; Lenarczyk R; Pluta S; Kowalski O; Pruszkowska P; Mazurek M; Swiątkowski A; Kalarus Z
    Kardiol Pol; 2014; 72(9):777-82. PubMed ID: 24846358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cardiac resynchronization therapy on patients with heart failure and narrow QRS complexes: a meta-analysis of five randomized controlled trials.
    Wang G; Zhao Z; Zhao S; Ding S; Shen S; Wang L
    J Interv Card Electrophysiol; 2015 Oct; 44(1):71-9. PubMed ID: 26162538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cardiac resynchronization in end-stage heart failure patients requiring inotrope therapy.
    Bhattacharya S; Abebe K; Simon M; Saba S; Adelstein E
    J Card Fail; 2010 Dec; 16(12):931-7. PubMed ID: 21111981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac resynchronization therapy in inotrope-dependent heart failure: a meta-analysis.
    Al-Shakarchi NJ; Ho JSY; Bray JJH; D'Ascenzo F; Duffy E; Hewett J; Adegbie D; Khan F; Kumar NS; Patel N; Ahmad M; Banerjee A; Haq I; Providencia R
    ESC Heart Fail; 2024 May; ():. PubMed ID: 38710670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis.
    Stavrakis S; Lazzara R; Thadani U
    J Cardiovasc Electrophysiol; 2012 Feb; 23(2):163-8. PubMed ID: 21815961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis.
    Adabag S; Roukoz H; Anand IS; Moss AJ
    J Am Coll Cardiol; 2011 Aug; 58(9):935-41. PubMed ID: 21851882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should cardiac resynchronization therapy be a rescue therapy for inotrope-dependent patients with advanced heart failure?
    Imamura T; Kinugawa K; Nitta D; Hatano M; Komuro I
    J Card Fail; 2015 Jun; 21(6):535-8. PubMed ID: 25930086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic importance of postoperative QRS widening in patients with heart failure receiving cardiac resynchronization therapy.
    Menet A; Bardet-Bouchery H; Guyomar Y; Graux P; Delelis F; Castel AL; Heuls S; Cuvelier E; Gevaert C; Ennezat PV; Tribouilloy C; Maréchaux S
    Heart Rhythm; 2016 Aug; 13(8):1636-43. PubMed ID: 27236025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac-resynchronization therapy in patients with systolic heart failure and QRS interval ≤130 ms: insights from a meta-analysis.
    Shah RM; Patel D; Molnar J; Ellenbogen KA; Koneru JN
    Europace; 2015 Feb; 17(2):267-73. PubMed ID: 25164431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay between right ventricular function and cardiac resynchronization therapy: an analysis of the CARE-HF trial (Cardiac Resynchronization-Heart Failure).
    Damy T; Ghio S; Rigby AS; Hittinger L; Jacobs S; Leyva F; Delgado JF; Daubert JC; Gras D; Tavazzi L; Cleland JG
    J Am Coll Cardiol; 2013 May; 61(21):2153-60. PubMed ID: 23541971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.
    Linde C; Abraham WT; Gold MR; St John Sutton M; Ghio S; Daubert C;
    J Am Coll Cardiol; 2008 Dec; 52(23):1834-1843. PubMed ID: 19038680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study.
    Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
    JACC Heart Fail; 2015 Sep; 3(9):691-700. PubMed ID: 26277764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial.
    Lee AY; Kutyifa V; Ruwald MH; McNitt S; Polonsky B; Zareba W; Moss AJ; Ruwald AC
    Heart Rhythm; 2015 Sep; 12(9):2010-7. PubMed ID: 26025322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy.
    Biton Y; Kutyifa V; Cygankiewicz I; Goldenberg I; Klein H; McNitt S; Polonsky B; Ruwald AC; Ruwald MH; Moss AJ; Zareba W
    Circ Heart Fail; 2016 Feb; 9(2):e002667. PubMed ID: 26823498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of the PR Interval in Patients Receiving Cardiac Resynchronization Therapy: Results From the REVERSE Study.
    Senfield J; Daubert C; Abraham WT; Ghio S; St John Sutton M; Cerkvenik J; Linde C; Gold MR
    JACC Clin Electrophysiol; 2017 Aug; 3(8):818-826. PubMed ID: 29759777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac resynchronization therapy in New York Heart Association class-IV patients dependent on intravenous drugs or invasive supportive treatments.
    Lee SS; Kwon HJ; Park KM; On YK; Kim JS; Park SJ
    ESC Heart Fail; 2020 Oct; 7(5):3109-3118. PubMed ID: 32790157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.
    Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
    JACC Heart Fail; 2017 Mar; 5(3):204-212. PubMed ID: 28254126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.